Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

British Journal of Cancer

Volumn 87, Issue 10, 2002, Pages 1072-1078

  Vasey, P A ^a,f   Roche H ^b   Bisset, D ^c   Terret, C ^b   Vernillet, L ^d   Riva, A ^d   Ramazeilles, C ^d   Azli, N ^d   Kaye, S B ^e   Twelves, C J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d SANOFI   (France)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Combination chemotherapy; Cyclophosphamide; Docetaxel; Dose finding; Metastatic breast cancer; Pharmacokinetics

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOMPERIDONE; FLUOROURACIL; GRANISETRON; LOPERAMIDE; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG EFFECT; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; NAUSEA; NEUROPATHY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TAXOIDS;

EID: 0037021267     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600626     Document Type: Article

References (43)

1. Adachi I, Watanabe T, Takashima S et al (1996) A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210-216
2. Alexopoulos CG, Rigatos G, Efremidis AP et al (1999) A phase II study of the effectiveness of docetaxel (Taxotere™) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology. Cancer Chemother Pharmacol 44: 253-258
3. Bissery MC, Nohynek G, Sanderink GJ et al (1995) Docetaxel (Taxotere™): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs, 6: 339-355
4. Brambilla C, Rossi A, Bonfante V et al (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261-266
5. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. J Pharmacokinet Biopharm 24: 153-172
6. Carmo-Pereira J, Costa FO, Henriques E et al (1987) A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471-473
7. Chevallier B, Fumoleau P, Kerbrat P et al (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322
8. Chollet P, Roché H, Twelves C et al (1998) A phase I-II study of Taxotere®, cyclophosphamide and rHuG-CSF (lenograstim) as first-line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 17: 205 (abstract)
9. Crown J, Fumoleau P, Kerbrat P et al (1997) Phase I trial of docetaxel with cisplatin as first-line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 16: 233 (abstract)
10. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Br J Cancer 74: 650-656
11. Fisher B, Anderson S, DeCillis A et al (1999) Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17: 3374-3388
12. Fisher B, Anderson S, Wickerham DL et al (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869
13. Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460
14. Frederiksen PL, Joergensen ST, Roesdahl K, Thomsen J, Mouridsen HT (1978) Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer Treat Rep 62: 449-450
15. Fumoleau P, Chevallier B, Kerbrat P et al (1996a) A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 7: 165-171
16. Fumoleau P, Delecroix V, Perrocheau G et al (1996b) Final results of a phase I dose finding and pharmacokinetic study of docetaxel in combination with vinorelbine in metastatic breast cancer. Ann Oncol 7 (Suppl 5): 606 (abstract)
17. Harris JR, Morrow M, Bonadonna G (1993) Cancer of the breast. In. Cancer: Principles and Practice of Oncology, DeVita Jr VT, Hellman S, Rosenberg SA (eds) pp 1264-1332. Philadelphia: Lippincott
18. Henderson IC (1991) Chemotherapy for metastatic disease. In. Breast Diseases, Harris JR, Hellman S, Henderson IC, Kinne DW (eds) pp 604-665. Philadelphia: Lippincott
19. Hudis CA, Seidman AD, Crown JPA et al (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58-65
20. Jain KK, Casper ES, Geller NL et al (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818-826
21. Kennedy MJ, Donehower RC, Sartorius SE, Chen TL, Rowinsky EK (1993) Sequences of Taxol and cyclophosphamide: A phase I and pharmacologic study in doxorubicin resistant metastatic breast cancer. Proc Am Soc Clin Oncol 12: 165 (abstract)
22. Kennedy MJ, Zahurak ML, Donehower RC et al (1996) Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783-791
23. Lortholary A, Maillart P, Delva R et al (1997) Docetaxel in combination with continuous infusion 5-fluorouracil in metastatic breast cancer patients after anthracycline failure: Phase I dose-escalation. Breast Cancer Res Treat, 46: 96 (abstract)
24. Marty M, Extra JM, Dieras V, Giacchetti S, Ohana S, Espie M (1992) A review of the antitumour activity of vinorelbine in breast cancer. Drugs 44 (Suppl 4): 29-35
25. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
26. Misset JL, Dieras V, Gruia G et al (1999) Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10: 553-560
27. Mouridsen HT (1992) Systemic therapy of advanced breast cancer. Drugs 44 (Suppl 4): 17-28
28. Nabholtz J-M, Smylie M, Mackey J et al (1997) Docetaxel/doxorubicin/cyclo-phosphamide in the treatment of metastatic breast cancer. Oncology 11 (Suppl 6): 25-27
29. Nabholtz J-M, Senn HJ, Bezwoda WR et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424
30. Pagani O, Sessa C, Martinelli G et al (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 8: 655-661
31. Pagani O, Sessa C, Martinelli G et al (1999) Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10: 539-545
32. Ravdin PM, Burris HA III, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracydine-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885
33. Richards MA, Hopwood P, Ramirez AJ et al (1992) Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life. Eur J Cancer, 28A: 1023-1028
34. Riva A, Fumoleau P, Roché H et al (1997) Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere™. Proc Am Soc Clin Oncol 16: 188 (abstract)
35. Rubens RD, Knight RK, Hayward JL (1975) Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32: 730-736
36. Schrijvers D, Wanders J, Dirix L et al (1993) Coping with the toxicities of docetaxel (Taxotere™). Ann Oncol 4: 610-611
37. Sjostrom J, Blomqvist C, Mouridsen H et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201
38. Steiner R, Stewart JF, Cantwell BM, Minton MJ, Knight RK, Rubens RD (1983) Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19: 1553-1557
39. Valero V, Holmes FA, Walters RS et al (1995) Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894
40. Valero V (1997) Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology 11 (Suppl 8): 34-36
41. Van Oosterom AT, Schrijvers D (1995) Docetaxel (Taxotere™): A review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs 6: 356-368
42. Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582: 273-278
43. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717